Screen Readers Skip to Content

Study Rejects Cancer Fear of Most Common Heartburn Treatments

Synopsis: Fears about the cancer causing effects of heartburn drugs put to rest after largest ever study.1

Author: Queen Mary University of London

Published: 2009-09-09

Main Digest

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

'Proton pump inhibitors' (PPI) are the most commonly used treatment for chronic acid reflux, or 'heartburn', a painful burning sensation in the chest, neck and throat which is experienced by almost a third of people in developed countries.

Regular and prolonged heartburn is known to cause 'benign oesophagitis', a reversible inflammation of the gullet. However if left untreated a condition called Barrett's Oesophagus (BE) occurs in around 10 per cent of sufferers, which can in turn develop into a potentially fatal cancer called esophageal adenocarcinoma.

BE is twice as common in the UK as it is in the USA, and esophageal cancer rates in the UK are the highest in the world; up to four times more common than in other European countries.

Despite their excellent safety record, it was unclear if long-term use of PPIs to reduce the discomfort of heartburn could increase the risk of developing either BE or the spread of the associated cancer.

New research carried out at Queen Mary, University of London and Leicester Royal Infirmary, has given the most conclusive evidence yet that this is not the case. The work is published in the peer reviewed journal Gut.

Professor Janusz Jankowski, who co-authored the study, said: "This is one of the most detailed studies investigating both the laboratory and clinical side of proton pump inhibitor drugs. As a consequence we are now better able to inform patients of the good benefit/risk ratio of this commonly prescribed therapy."

Tests carried out during the two-year study looked at tissue sampled from the Oesophagus lining of ninety volunteers, each of whom were given PPI drugs at either a high or low dosage. Researchers found there was no difference in the rate at which BE developed, neither was there a change in the number of precancerous cells in either group.

While there had also been fears about how the treatments might affect people already suffering from BE, the study also showed that there was no evidence that this led to any worsening of the condition or any extra incidences of cancer.

BE is marked by changes in the cells of the esophagus lining (squamous epithelium) that makes them more like the cells of the intestines (columnar epithelium). As well as increasing the risk of esophageal cancer, the condition narrows the esophagus and patients can experience pain whilst swallowing. The chance of cancer developing is proportional to the length of BE.

PPIs work by blocking the action of gastrin, a hormone that controls acid levels in the stomach, and is known to increase the normal movement of cells in the gastro-intestinal tract. Since PPI therapy increases the levels of gastrin in the body, it had been thought this could cause expansion of BE affected tissue, but this was not found to be the case: the scientists observed neither expansion or contraction of the abnormal tissue. This is concordant with current UK practice, where PPI therapy is currently only licensed to treat heartburn and 'oesophagitis' but not BE.

Reference: Professor Janusz Jankowski holds the Sir James Black chair in Gastrointestinal Biology and Trials at the Center for Gastroenterology, Barts and The London School of Medicine and Dentistry at Queen Mary, University of London.

Gut is a leading international journal in gastroenterology and has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, reviews and commentaries. The journal has an authoritative global Editorial Board and a growing international readership. Gut is the official journal of the British Society of Gastroenterology.

Related Medical Research Documents

Full List of Medical Research Publications

Recent Disability News and Updates

Full List of Disabled World News Updates


Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.

Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information.

Cite Page: Journal: Disabled World. Language: English (U.S.). Author: Queen Mary University of London. Electronic Publication Date: 2009-09-09. Last Revised Date: 2009-09-09. Reference Title: Study Rejects Cancer Fear of Most Common Heartburn Treatments, Source: <a href=https://www.disabled-world.com/news/research/heartburn-treatment-cancer.php>Study Rejects Cancer Fear of Most Common Heartburn Treatments</a>. Abstract: Fears about the cancer causing effects of heartburn drugs put to rest after largest ever study. Retrieved 2021-03-01, from https://www.disabled-world.com/news/research/heartburn-treatment-cancer.php - Reference Category Number: DW#108-2236.